Donoghue Forlines’s Royalty Pharma RPRX Stock Holding History

Donoghue Forlines’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-42,687	Closed	-$1.21M	–	247
2024 Q3	$1.21M	Buy	42,687 +20,211	+90%	+$560K	0.34%	105
2024 Q2	$593K	Buy	22,476 +1,719	+8%	+$47.7K	0.17%	139
2024 Q1	$630K	Buy	+20,757	New	+$612K	0.18%	143
2023 Q3	–	Sell	-11,712	Closed	-$360K	–	279
2023 Q2	$360K	Sell	11,712 -6,723	-36%	-$228K	0.11%	200
2023 Q1	$664K	Buy	18,435 +12,916	+234%	+$479K	0.24%	114
2022 Q4	$218K	Sell	5,519 -1,037	-16%	-$43.3K	0.08%	211
2022 Q3	$263K	Sell	6,556 -9,359	-59%	-$400K	0.09%	187
2022 Q2	$669K	Buy	15,915 +3,133	+25%	+$128K	0.17%	144
2022 Q1	$498K	Buy	+12,782	New	+$502K	0.11%	250

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Donoghue Forlines's RPRX Position: Q4 2024 in Review

Donoghue Forlines sold out of Royalty Pharma (RPRX) in Q4 2024, closing a stake of 42,687 shares — an estimated $1.21M sold.

Donoghue Forlines first reported a position in RPRX in Q1 2022 and held it in 9 quarters. The position peaked at $1.21M in Q3 2024. 417 funds tracked by Wall St. Rank hold RPRX as of Q4 2024.

Donoghue Forlines reported no remaining Royalty Pharma position as of Q4 2024 after selling out during the quarter.
Donoghue Forlines sold 42,687 Royalty Pharma shares in Q4 2024, an estimated $1.21M.
Donoghue Forlines first reported a position in Royalty Pharma in Q1 2022 and held it in 9 quarters.
Donoghue Forlines's Royalty Pharma position peaked at $1.21M in Q3 2024.
417 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2024.

Based on Donoghue Forlines's 13F filing for Q4 2024, filed 17 Jan 2025.